Royalty Pharma plc (RPRX) Cash Flow Statement

The persistent gap between net income and operating cash flow suggests that reported earnings understate the company's cash-generating ability, likely due to non-cash charges or non-operating losses. For instance, in 2026Q2, net income was only $17.9M while operating cash flow reached $1.4B, implying substantial non-cash or non-operating deductions. This divergence warrants further investigation into the composition of net income, as it may indicate that the royalty model's cash flows are more robust than GAAP earnings suggest.

The free cash flow trajectory shows resilience, with FCF margins typically above 100% except for 2026Q2's 2.1% margin, which is distorted by a large working capital swing. Excluding that quarter, FCF margins have been consistently strong, indicating that the royalty business generates substantial cash relative to revenue. However, the volatility in FCF margins, particularly the 2026Q2 outlier, suggests that working capital movements can significantly impact reported cash flows, and investors should monitor these fluctuations.

The working capital changes are substantial and erratic, with the 2026Q2 negative $835.2M change being a major driver of the quarter's elevated operating cash flow. This suggests that the company's cash flow is not purely recurring but subject to timing differences in royalty collections and other operating items. The large positive swing in 2026Q1 and negative in 2026Q2 may indicate a pattern of quarterly volatility that investors should factor into their cash flow projections.

The company has maintained a steady dividend payout, which appears sustainable given the robust operating cash flow. Buyback activity has been more variable, with significant repurchases in 2025Q1 and 2025Q2, suggesting management may be using excess cash to repurchase shares when they perceive undervaluation. However, the lack of acquisition data in most quarters implies that capital deployment is primarily focused on returning cash to shareholders rather than external growth, which aligns with the royalty business model.